ChemoCentryx (CCXI) Getting Somewhat Positive News Coverage, Analysis Shows
Press coverage about ChemoCentryx (NASDAQ:CCXI) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ChemoCentryx earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.7229385540442 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of CCXI opened at $10.77 on Monday. The firm has a market cap of $529.35 million, a PE ratio of 29.92 and a beta of 1.36. ChemoCentryx has a 12-month low of $5.42 and a 12-month high of $15.08. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.51.
ChemoCentryx (NASDAQ:CCXI) last issued its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. The firm had revenue of $15.02 million during the quarter, compared to analyst estimates of $16.88 million. ChemoCentryx had a net margin of 18.69% and a return on equity of 39.31%. analysts predict that ChemoCentryx will post -0.86 EPS for the current year.
In other news, insider Markus J. Cappel sold 25,179 shares of the business’s stock in a transaction on Friday, June 29th. The shares were sold at an average price of $13.67, for a total transaction of $344,196.93. Following the completion of the sale, the insider now directly owns 24,626 shares of the company’s stock, valued at $336,637.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Susan M. Kanaya sold 49,507 shares of the business’s stock in a transaction on Thursday, June 28th. The shares were sold at an average price of $13.79, for a total transaction of $682,701.53. Following the sale, the chief financial officer now directly owns 38,985 shares of the company’s stock, valued at $537,603.15. The disclosure for this sale can be found here. Insiders have sold 76,436 shares of company stock valued at $1,050,371 over the last three months. Insiders own 14.50% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.